The oral AntibioticS approprIateness score (OASIS) – A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF)

C. Orchard, S. Srivastava, J. Burgess, N. Simmonds, D. Bilton, E. H. Baker (London, United Kingdom)

Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Session: Cystic fibrosis: clinical problems and microbiology in adults
Session type: Thematic Poster Session
Number: 1178
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Orchard, S. Srivastava, J. Burgess, N. Simmonds, D. Bilton, E. H. Baker (London, United Kingdom). The oral AntibioticS approprIateness score (OASIS) – A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF). Eur Respir J 2013; 42: Suppl. 57, 1178

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
High frequency chest wall oscillation (HFCWO) in the treatment of acute pulmonary exacerbation in adult cystic fibrosis (CF) patients
Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children
Year: 2013


Increased systemic inflammation in cystic fibrosis (CF) is associated with deterioration in lung clearance index (LCI)
Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology
Year: 2014

Early detection of pulmonary exacerbations in children with cystic fibrosis by electronic home monitoring of symptoms and lung function
Source: International Congress 2016 – Cystic fibrosis: monitoring and management
Year: 2016


Lung function and early abnormality of glucose tolerance (GT) in cystic fibrosis (CF) patients
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013


Nebulised antibiotics with the I-neb adaptive aerosol delivery (AAD) system: Impact on adherence in cystic fibrosis (CF) patients
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems
Year: 2012


Differences in clinical features and biomarkers of subsequent acute cystic fibrosis pulmonary exacerbations - Analysing exacerbations as separate entities
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013


Lung Clearance Index (LCI) and FEV1 on the evaluation of the effect of tobramycin solution for inhalation (TIS) among patients with cystic fibrosis
Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment
Year: 2014


Assessment of the work of breathing (sWOB) within different functional and genetic groups in patients with cystic fibrosis (CF)
Source: Annual Congress 2013 –New perspectives of lung function assessment in children
Year: 2013



Early eradication of pseudomonas aeruginosa (PA) in cystic fibrosis patients (CF): Which is the best treatment?
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013


Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015


Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016


Indicators of pulmonary exacerbation in adults with cystic fibrosis (CF)
Source: Annual Congress 2011 - Cystic fibrosis: New aspects of diagnosis, inflammation and detecting exacerbation
Year: 2011



Macrolides in cystic fibrosis (CF); clinical experience
Source: Eur Respir J 2004; 24: Suppl. 48, 615s
Year: 2004

Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016


Vitamin D serum level and pulmonary exacerbations in children with cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013


Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients
Source: Eur Respir J 2002; 20: Suppl. 38, 342s
Year: 2002

Frequency and pathogenicity of rhinovirus associated pulmonary exacerbations in patients with cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children
Year: 2013

Safety, tolerability and efficacy of intravenous aminophylline in adult patients with pulmonary exacerbations of cystic fibrosis
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014

Omalizumab for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in children with cystic fibrosis (CF)
Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment
Year: 2014


Monitoring small airways disease (SAD) in cystic fibrosis (CF)
Source: Annual Congress 2011 - Monitoring with lung function tests in airway diseases
Year: 2011